Quantcast

Latest Histone deacetylase Stories

2009-06-12 09:28:50

Three female mice have been cloned until now. The first mouse was born on 12 May, the second is now 10 days old and the third is only two days old. Scientists are studying how to improve the efficiency of the cloning process Universitat Autònoma de Barcelona (UAB) researchers are the first to have cloned mice in Spain. Cloe, Cleo and Clona are three female brown-coloured mice and were born respectively on 12 May, 3 June and 10 June. By means of nuclear transfer techniques,...

2009-06-04 09:17:35

Latent HIV genes can be 'smoked out' of human cells. The so-called 'shock and kill' technique, described in a preclinical study in BioMed Central's open access journal Retrovirology, might represent a new milestone along the way to the discovery of a cure for HIV/AIDS.Dr. Enrico Garaci, president of the Istituto Superiore di Sanità (the Italian Institute of Health) and Dr. Andrea Savarino, a retrovirologist working at the institution, worked with a team of researchers to...

2009-05-28 14:12:00

SHENZHEN, China and SAN DIEGO, May 28 /PRNewswire/ -- Shenzhen Chipscreen Biosciences, Ltd., and HUYA Bioscience International, LLC, today announced that final data from a Phase 1 trial conducted by Chipscreen of the investigational compound chidamide (CS055/HBI-8000) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009, in Orlando, Florida. Chidamide/HBI-8000 is a novel benzamide class histone deacetylase...

2009-05-11 06:56:43

MIT researchers who were previously able to reverse the signs of Alzheimer's disease in mice have now identified the specific gene involved in the process. The gene, called HDAC2, is part of a family of genes known to regulate gene expression by modifying a structure in the cell nucleus called chromatin. When HDAC is inhibited, this structure is loosened up, effectively letting other important genes express themselves. When the researchers gave HDAC2 inhibiting drugs to mice who were bred to...

2009-04-29 08:22:10

HDAC inhibitor effective against tumor cell linesA laboratory study by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that an anti-cancer compound studied for treating blood cancers may also help in treating cancers of the head and neck. The work is reported in the April 28th online edition of the Journal of Pathology.Head and neck cancer refers to tumors in the mouth, throat, or larynx (voice box). Each year about 40,000 men and women develop head and neck...

2009-04-17 07:30:00

Pharmacyclics to maintain all US Rights Conference Call to discuss the company's third quarter financial results is scheduled for April 23, 2009 at 11:00 a.m. EDT (8:00 a.m. PDT). SUNNYVALE, Calif., April 17 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has entered into a global strategic alliance with Servier, the leading French independent pharmaceutical company. The alliance will focus on the research, development, and commercialization of...

2009-04-03 12:51:19

Today, during the 87th General Session of the International Association for Dental Research, convening at the Miami Beach Convention Center, a group of scientists from Nihon University (Tokyo, Japan) will present findings suggesting that periodontal disease could act as a risk factor for reactivating latent HIV-1 in affected individuals.Latently infected cells harbor HIV-1 proviral DNA genomes integrated with heterochromatins, allowing for the persistence of transcriptionally silent...

2008-12-01 14:00:00

SINGAPORE, Dec. 1 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF). The trial is designed to evaluate the safety and tolerability of SB1518 in patients with CIMF and is expected to enrol up to 50 patients. The Phase 1 part of the study will assess the safety profile and evaluate the pharmacokinetic...

2008-10-21 09:00:12

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the presentation of a poster highlighting preclinical synergy of Cyclacel's sapacitabine when given in combination with histone deacetylating agents (HDAC) valproate and vorinostat. The data will be presented at the 20th Annual European Organization for Research and Treatment of Cancer-National Cancer Institute-American Academy of Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer...

2008-10-03 12:00:05

MethylGene, a clinical stage biopharmaceutical company, has announced that Health Canada has approved the company's clinical trial application for MGCD290, a fungal Hos2 histone deacetylase inhibitor to be used in combination with azoles for the treatment of fungal infections. MethylGene expects to initiate a Phase I clinical trial in Canada in October 2008. The goal of this trial will be to assess the safety, pharmacokinetics and tolerability of the compound in healthy volunteers. MGCD290...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.